Honegger A, Dull T J, Bellot F, Van Obberghen E, Szapary D, Schmidt A, Ullrich A, Schlessinger J
Rorer Biotechnology, Inc., King of Prussia, PA 19406.
EMBO J. 1988 Oct;7(10):3045-52. doi: 10.1002/j.1460-2075.1988.tb03169.x.
In vitro site-directed mutagenesis was used to replace individually the three known autophosphorylation sites of the epidermal growth factor (EGF)-receptor (i.e. Tyr1173, Tyr1148 and Tyr1068) by phenylalanine, a residue which cannot serve as a phosphate acceptor site. In another mutant, Tyr1173 was substituted by a serine residue. The cDNA constructs encoding either mutant or wild-type EGF-receptors were transfected into NIH-3T3 cells devoid of endogenous EGF-receptors. The mutant receptors were expressed on the cell surface and displayed typical high- and low-affinity binding sites for [125I]EGF. Phorbol ester (PMA) modulated the binding affinity of wild-type and mutant receptors in a similar manner. Mutant EGF-receptors exhibited EGF-dependent tyrosine kinase activity leading to self-phosphorylation and phosphorylation of exogenous substrates both in vitro and in living cells. The internalization and degradation of EGF-receptors were not affected by the mutations. Cells expressing mutant EGF-receptors became mitogenically responsive to EGF, indicating that none of the vital functions of the EGF-receptor were critically impaired by the loss of individual autophosphorylation sites. Maximal mitogenic stimulation correlated with the number of wild-type or mutant receptors per cell, highly expressing cells showing higher maximal stimulation. However, the dose-response curves of cells expressing mutant receptors were slightly shifted to lower concentrations of EGF, rendering the cells mitogenically responsive to lower doses of EGF than cells expressing normal EGF-receptor at similar expression levels. Basal [3H]thymidine incorporation in the presence of 0.5% calf serum was consistently higher for cells expressing mutant receptors, while the response to stimulation with 10% calf serum was not affected.
采用体外定点诱变技术,将表皮生长因子(EGF)受体的三个已知自磷酸化位点(即Tyr1173、Tyr1148和Tyr1068)分别替换为苯丙氨酸,苯丙氨酸是一种不能作为磷酸受体位点的残基。在另一个突变体中,Tyr1173被丝氨酸残基取代。将编码突变型或野生型EGF受体的cDNA构建体转染到缺乏内源性EGF受体的NIH-3T3细胞中。突变型受体在细胞表面表达,并显示出对[125I]EGF的典型高亲和力和低亲和力结合位点。佛波酯(PMA)以类似方式调节野生型和突变型受体的结合亲和力。突变型EGF受体表现出EGF依赖性酪氨酸激酶活性,导致体外和活细胞中自身磷酸化以及外源底物的磷酸化。EGF受体的内化和降解不受这些突变的影响。表达突变型EGF受体的细胞对EGF产生有丝分裂反应,表明单个自磷酸化位点的缺失并未严重损害EGF受体的任何重要功能。最大有丝分裂刺激与每个细胞中野生型或突变型受体的数量相关,高表达细胞显示出更高的最大刺激。然而,表达突变型受体的细胞的剂量反应曲线略微向较低浓度的EGF偏移,使得这些细胞在与表达正常EGF受体且表达水平相似的细胞相比时,对较低剂量的EGF产生有丝分裂反应。在含有0.5%小牛血清的情况下,表达突变型受体的细胞中基础[3H]胸苷掺入量始终较高,而对10%小牛血清刺激的反应不受影响。